MTMR7 Human Pre-designed siRNA Set A

Cat. No.: M1479547

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Übersicht

MTMR7 Human Pre-designed siRNA Set A contains three designed siRNAs for MTMR7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components MTMR7 siRNA-1: 5 nmol (HPLC) MTMR7 siRNA-2: 5 nmol (HPLC) MTMR7 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Product Line

Biologische Produkte

Application Protocols

The following protocol is general literature guidance for siRNA transfection and should be optimized empirically. Item-specific instructions are not provided for this product.

A. Preparation

• Thaw siRNA on ice. Spin briefly. Reconstitute in RNase-free water or 1× TE to 10–100 µM. Aliquot and store at −20°C.
• Prepare cells 18–24 h prior to transfection to reach 40–70% confluence at the time of dosing.

B. Complexation (lipid-based example)

• Dilute siRNA in serum-free medium to 2× the intended final concentration (e.g., 10–100 nM).
• Separately dilute transfection reagent according to the manufacturer’s IFU.
• Combine equal volumes, gently mix, and incubate 10–30 min at room temperature to form complexes.

C. Transfection

• Replace culture medium with fresh serum-free medium (if required) and add complexes dropwise.
• After 4–6 h, replace with complete growth medium (per reagent guidance). Alternatively, perform reverse transfection during cell seeding.

D. Assessment

• mRNA knockdown: RT-qPCR at 24–48 h.
• Protein knockdown: Immunoblot/ELISA at 48–96 h.
• Cytotoxicity: Include viability assay (e.g., resazurin/ATP-based) to separate delivery effects from on-target biology.

Controls

• Non-targeting siRNA, transfection-only control, and positive-control siRNA. Consider rescue with siRNA-resistant MTMR7 cDNA where appropriate.

Biological Roles

Target gene context (literature):

• MTMR7 encodes a member of the myotubularin family of lipid phosphatases that act on phosphatidylinositol phosphates, notably PI3P and/or PI(3,5)P2 in various family members. These lipids regulate endosomal trafficking, membrane dynamics, and signaling.
• Myotubularin-related proteins often function as homo-/heterodimers and localize to endosomal or related membrane compartments, influencing vesicular sorting and autophagic pathways.
• Silencing MTMR7 with siRNA enables interrogation of its contribution to phosphoinositide turnover, endosome maturation, receptor trafficking, and downstream signaling node modulation in human cells.

Use of this product (general):

• The MTMR7 Human Pre-designed siRNA Set A provides a tool to transiently reduce MTMR7 transcript levels to study gene function, pathway placement, and redundancy/compensation within the myotubularin family.

Item-specific notes:

• Sequence(s), target transcript isoforms, and predicted off-target analyses are not specified for this item; refer to CoA/Spec Sheet for any available annotation. Users should verify target isoform coverage based on their cell model’s expression profile (e.g., RNA-seq or RT-PCR).

Buffer Applications

Although not a buffer component itself, this siRNA set requires compatible RNase-free buffers for reconstitution, storage, and delivery.

General/literature guidance:

• Reconstitution buffers: RNase-free water or 1× TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5–8.0). TE enhances stability by chelating divalent cations.
• Working buffers/media: Serum-free medium (e.g., Opti-MEM or equivalent) during lipid complexation, followed by complete growth medium after 4–6 h (per transfection reagent guidance).
• pH range: Maintain near-neutral pH (6.8–8.0) for stability and optimal transfection complex formation.
• Salt/ion considerations: Physiologic ionic strength supports duplex integrity; avoid Mg2+/Ca2+ in storage unless chelated (EDTA) to mitigate RNase activity.
• Filtration: Use 0.22 µm low-binding filters only if sterility is required; excessive filtration may cause adsorption losses at low concentrations.

Practical tips:

• Prepare concentrated stocks to minimize adsorption to plastics; use low-retention tubes and tips.
• Include nuclease inhibitors only when compatible with downstream biology; many are unnecessary if aseptic, RNase-free technique is maintained.

Item-specific buffer recommendations are not specified for this item; refer to CoA/Spec Sheet and the chosen transfection reagent’s IFU.

Green Alternatives

siRNA-based experiments are inherently aqueous and typically avoid hazardous organic solvents, aligning well with green chemistry principles.

• Current product context: An RNA oligonucleotide set reconstituted in water or mild buffers; no halogenated solvents, heavy-metal catalysts, or high-energy processes are intrinsic to its use.

Greener practice recommendations (general):

• Use RNase-free water or TE for reconstitution; prepare concentrated stocks to minimize plastic and reagent consumption.
• Prefer serum-free complexation phases with quick transition back to complete medium to reduce waste.
• Choose low-toxicity, biodegradable transfection reagents where feasible; evaluate lipid dose minimization to reduce cytotoxic waste.
• Consolidate experiments using multiwell miniaturization to decrease reagent volumes and consumables.
• Decontamination and cleaning with low-VOC, biodegradable RNase deactivators where validated.

Comparison (general, illustrative):

• Conventional approach: Legacy transfections sometimes employed large volumes of organic co-solvents or chloroform-extracted carriers.
• Greener alternative: Modern cationic lipids/polymers operate in fully aqueous systems; lipid nanoparticles are formulated without chlorinated solvents in many workflows.

Waste considerations:

• Segregate biohazardous waste and follow institutional green lab programs. Where possible, recycle tip boxes and secondary packaging. Avoid DEPC in favor of commercially prepared nuclease-free water to eliminate hazardous handling.

Pharmaceutical Uses

This product is supplied strictly for research use and is not intended for human or veterinary use, diagnostic procedures, or clinical applications.

General/literature context (non-clinical):

• siRNAs are used in pharmaceutical research as tools to validate targets, map pathways, and de-risk mechanisms prior to small-molecule or biologic development.
• Preclinical formulation research often evaluates delivery systems such as cationic lipids, polymers, or lipid nanoparticles (LNPs) to optimize cellular uptake and stability; such activities are outside the scope of this catalog item and must follow appropriate regulatory and safety frameworks.
• Excipients commonly explored in formulation R&D (e.g., citrate, phosphate buffers, PEG-lipids) are not components of this product; no formulation excipients are specified for this item.

Regulatory note:

• No pharmacopeial status, dosage form, or GMP grade is claimed or specified for this item; refer to CoA/Spec Sheet. Any translational or manufacturing use would require separate sourcing, documentation, and compliance not provided here.

Physical Properties

Item-specific physicochemical data are not provided for this siRNA set.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight (per duplex or pool): Not specified for this item; refer to CoA/Spec Sheet.
• Extinction coefficient (ε260): Not specified for this item; refer to CoA/Spec Sheet.
• Concentration (OD260 to mass conversion): Not specified for this item; refer to CoA/Spec Sheet.

General/literature information for siRNA reagents (for planning only):

• Solubility: Highly soluble in nuclease-free water and low-ionic-strength Tris/EDTA buffers. Avoid solutions containing divalent cations without chelators, which can promote nuclease activity.
• pH stability: siRNA is most stable near neutral pH (pH 6.5–8.0). Acidic or highly basic conditions can promote depurination/deamination or backbone cleavage over time.
• Thermal behavior: Duplexes melt (Tm) typically between ~60–85°C depending on length, base composition, salt, and modifications (literature). Exact Tm for this item is not specified.
• Storage form: Lyophilized or aqueous; stability is enhanced by storage at ≤−20°C, desiccation (if dry), and protection from RNases and repeated freeze–thaw cycles (literature guidance).

Note: For experiment-critical parameters (e.g., OD260, ε260, exact solvent and pH recommendations), consult the item’s CoA/Spec Sheet and SDS.

Quality and Grades

• Item-specific grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

Context on siRNA quality (general, literature):

• Purification: siRNAs are commonly supplied as desalted, cartridge-purified, or HPLC/ PAGE-purified duplexes. Higher-purity materials reduce truncated species and can improve knockdown consistency. The purification method for this item is not specified.
• Composition of “Set A”: A pre-designed set typically includes multiple siRNAs targeting MTMR7 to increase on-target silencing probability across cell lines/conditions. The number of duplexes, individual sequences, and any chemical modifications are not specified for this item.
• QC metrics: Common metrics include OD260, concentration, residual salts/solvents, identity confirmation by MS or LC, and nuclease contamination testing. Item-specific QC metrics are not specified; refer to CoA/Spec Sheet.
• Performance expectations: Pre-designed sets are selected using transcript annotations and off-target prediction algorithms (literature). Actual knockdown efficiency depends on cell type, transfection method, dose, exposure time, and target expression.

Implications for users:

• If conducting quantitative phenotyping or RNA-seq, prefer verified purity and sequence documentation (CoA) and include multiple independent siRNA sequences with concordant phenotypes.
• Validate knockdown at both mRNA (RT-qPCR) and protein levels (immunoblot or immunoassay), and monitor cytotoxicity to discriminate sequence-specific effects from delivery toxicity.

Reaction and Applications

As an siRNA reagent, this product is used for sequence-specific post-transcriptional gene silencing of human MTMR7 via the RNA interference (RNAi) pathway.

Applications (general, literature):

• Transient knockdown of MTMR7 in cultured human cells to interrogate functional roles in phosphoinositide metabolism, endosomal trafficking, or signaling cascades.
• Phenotypic screening using “Set A” to identify concordant on-target phenotypes across multiple siRNAs and prioritize hits for follow-up.
• Pathway mapping: Combination knockdowns with other genes to test epistasis or synthetic interactions.
• Assay readouts: RT-qPCR for mRNA, immunoblot/ELISA for protein, microscopy for trafficking phenotypes, and lipid probes for PI3P/PI(3,5)P2 dynamics.

Practical tips (general):

• Optimize transfection reagent, cell density, and siRNA dose (typical 1–50 nM final; literature) to balance knockdown with viability.
• Time course: Assess mRNA at 24–48 h and protein at 48–96 h post-transfection, depending on protein half-life.
• Controls: Include a non-targeting siRNA, positive knockdown control, and (if feasible) siRNA-resistant rescue constructs.
• Pooling: If provided as multiple duplexes, test individually and as a pool to evaluate potency and off-target risk.

Note: Exact composition, number of duplexes, and any chemical modifications are not specified for this item; consult the CoA/Spec Sheet for item-specific application notes if available.

Reaction Conditions

Chemical reaction conditions are not applicable to this product. The following guidance pertains to experimental conditions for siRNA use (general, literature):

• Reconstitution: Add RNase-free water or TE to achieve a stock concentration suitable for your workflow (e.g., 10–100 µM). Mix gently; avoid vigorous vortexing of dilute solutions to prevent foaming and adsorption.
• Complex formation: Combine siRNA with a compatible transfection reagent in serum-free medium; incubate ~10–30 min at ambient temperature to allow complexation (follow reagent IFU).
• Dosing: Typical final concentrations are 1–50 nM in cell culture, optimized per cell line and endpoint. Start with a small matrix (e.g., 5, 10, 20 nM) and include toxicity monitoring.
• Incubation: Replace with complete medium after 4–6 h if required by the reagent. Assess mRNA knockdown at 24–48 h; protein at 48–96 h.
• Controls: Non-targeting siRNA, positive knockdown control, and transfection-only control.

Item-specific concentrations, volumes, and timing are not provided; refer to CoA/Spec Sheet and the transfection reagent manufacturer’s protocol for authoritative instructions.

Safety and Handling

• GHS classification, signal word, pictograms, and H-statements: Not specified for this item; refer to SDS.
• Research use: For research use only. Not for diagnostic, therapeutic, or in vivo human/animal use.

Good molecular biology practice (general, literature):

• RNase control: Work in an RNase-free area. Use RNase-free water, tips, and tubes. Wear clean gloves and change them frequently. Wipe surfaces and equipment with RNase-decontamination solutions.
• Personal protective equipment (PPE): Laboratory coat, gloves, and safety glasses are recommended when handling powders or solutions. Avoid inhalation of lyophilized material and contact with eyes/skin.
• Handling: Minimize aerosol generation. Reconstitute gently to avoid shearing. Keep solutions on ice during setup for cell-based assays.
• Incompatibilities: Avoid strong acids/bases and oxidants that may degrade RNA. Avoid nuclease-contaminated reagents or biological materials.
• First aid (general): In case of skin/eye contact, rinse with water. If inhaled, move to fresh air. If ingested, rinse mouth with water. Seek medical attention if irritation persists. Always defer to the SDS for authoritative guidance.
• Spill/cleanup: For small spills, absorb with inert material and clean with RNase-decontamination solution, then water. Dispose according to institutional and local regulations.
• Waste: Dispose of oligonucleotide waste and contaminated consumables as laboratory chemical/biological waste per institutional SOPs.

Solvent Selection

This product is an RNA oligonucleotide set; dissolution is performed in aqueous, RNase-free media rather than organic solvents.

• Item-specific solvent: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature):

• Primary choices: RNase-free water, 1× TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5–8.0), or 10 mM Tris-HCl (pH 7.5–8.0). TE provides EDTA to chelate divalent cations and enhance nuclease resistance during storage.
• Avoid: Buffers containing Mg2+/Ca2+ unless needed for downstream enzymology; repeated freeze–thaw; and solutions with RNases (e.g., non-treated water, contaminated tips/tubes).
• Working dilutions: Prepare concentrated stocks (e.g., 10–100 µM, literature) and dilute into serum-free transfection medium immediately before complexation with lipids/polymers.

Comparison (general):

• RNase-free water: Maximal versatility; slightly less long-term stability than TE.
• TE buffer: Improved storage stability via chelation; EDTA may be undesirable for certain Mg2+-dependent downstream enzymes.

Note: Filter-sterilize and use nuclease-free plastics. If combining with organic delivery vehicles (e.g., cationic lipids), follow the manufacturer’s solvent/medium recommendations for complex formation.

Storage and Reconstitution

Item-specific storage and shipping:

• Storage Conditions: Store at −20°C (per product data).
• Shipped In: Ice chest + Ice pads (per product data).

Item-specific appearance, concentration, and solvent are not specified; refer to CoA/Spec Sheet.

General/literature guidance:

• Upon receipt: If lyophilized, allow to equilibrate to room temperature in a desiccator before opening to prevent condensation. If in solution, keep on ice during handling.
• Reconstitution: Use RNase-free water or 1× TE (pH 7.5–8.0). Prepare a concentrated stock (e.g., 10–100 µM). Mix by gentle pipetting; avoid repeated vortexing.
• Aliquoting: Dispense single-use aliquots to avoid freeze–thaw cycles. Use low-retention, RNase-free tubes.
• Storage: −20°C for medium-term; −80°C for long-term. Protect from light if fluorophore-conjugated (no conjugation is specified for this item). Avoid more than 3–5 freeze–thaw cycles; thaw on ice.
• Stability: siRNA is generally stable for months at −20°C and longer at −80°C when stored in TE. Working dilutions should be kept at 4°C for short periods (≤1–2 weeks) or prepared fresh as needed.

Always consult the product’s CoA/Spec Sheet and SDS for item-specific guidance and stability data.

Structure and Identity

A predesigned small interfering RNA (siRNA) set targeting human MTMR7 (myotubularin-related protein 7), supplied for research use.

• Item-specific identifiers:

  • Product Name: MTMR7 Human Pre-designed siRNA Set A (SKU: M1479547)
  • Target species: Human (Homo sapiens)
  • Target gene: MTMR7
  • CAS: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey / SMILES: Not applicable to oligonucleotide mixtures; not provided for this item.

• Structural features (general, literature):

  • siRNA reagents are typically double-stranded RNA duplexes (~19–23 bp) with 2-nt 3′ overhangs and 5′-phosphate/3′-hydroxyl termini. Exact length, chemistry, and any stabilizing modifications (e.g., 2′-O-Me, 2′-F, phosphorothioate linkages) are not specified for this item.
  • “Set A” commonly denotes a pool or panel of multiple distinct siRNA duplexes targeting non-overlapping regions of the MTMR7 transcript to enhance knockdown robustness and mitigate off-target effects. The number of duplexes and their sequences are not specified for this item; refer to CoA/Spec Sheet.

• 2D description (general, literature):

  • Each duplex comprises an antisense (guide) strand complementary to the MTMR7 mRNA region and a sense (passenger) strand. The duplex adopts A-form helical RNA geometry under physiological ionic strength.

Synthetic Utility

Not typically applicable. This product is a functional gene-silencing reagent rather than a synthetic building block or reaction substrate.

For users planning method development (general, literature):

• siRNA can be used as a tool in synthetic biology or chemical biology workflows to modulate enzyme levels, enabling condition-dependent synthesis or pathway rerouting in cell-based systems.
• Chemical conjugation (e.g., fluorophores, biotin) to siRNA is sometimes employed for trafficking studies; however, no such modifications are specified for this item. Any customization should be performed on separate, appropriately specified materials.

Target Specificity

Information limited to product data:

• Target: MTMR7 (human)
• Product: MTMR7 Human Pre-designed siRNA Set A (SKU: M1479547)

Item-specific details such as target transcript IDs/isoforms, siRNA sequences, number of duplexes in the set, predicted off-targets, and chemical modifications are not specified for this item; refer to CoA/Spec Sheet. Users should confirm that the targeted regions are expressed in their cell system and consider isoform-specific assays if relevant.

Häufig gestellte Fragen

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.